According to the new market research report “North American Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT — Technetium, PET- F-18), Therapeutic (Beta Emitters — I-131, Alpha Emitters, Brachytherapy — Y-90)), by Application (Oncology, Cardiology) — Forecasts to 2020”, published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints/challenges, and opportunities.
Don’t miss out on business opportunities in “Radiopharmaceuticals Market”. Speak to our analyst and gain crucial industry insights that will help your business grow: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=417
Early buyers will receive 10% customization on reports.
This report studies the North American Nuclear Medicine/Radiopharmaceuticals market for the forecast period of 2015 to 2020. This market is expected to reach USD 2.98 Billion by 2020 from USD 1.97 Billion in 2015, at a CAGR of 8.6%.
Based on application, the North American nuclear medicine/radiopharmaceuticals market is segmented into SPECT, PET, and therapeutic applications. In 2015, the cardiology application accounts for the largest share of North American nuclear medicine/radiopharmaceuticals market for SPECT applications. This large share can be attributed to new hardware and software designs in SPECT, rising incidence rate of CVDs, and adoption of SPECT in new cardiac applications.
Browse and in-depth TOC on “Radiopharmaceuticals Market”
92 — Tables
60 — Figures
180 — Pages
View more detailed TOC @ https://www.marketsandmarkets.com/Market-Reports/radiopharmaceuticals-market-417.html
Health Inc. (U.S.), Mallinckrodt plc (Ireland), GE Healthcare (U.K.), Lantheus Medical Imaging, Inc. (U.S.), Bayer Healthcare (Germany), Bracco Imaging S.p.A (Italy), Eczacibasi-Monrol Nuclear Products (Turkey), Nordion, Inc. (Canada), Advanced Accelerator Applications S.A. (France), and IBA Molecular Imaging (Belgium).
Request for Free Sample Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=417